205 related articles for article (PubMed ID: 9748584)
1. Mutagenic properties of topoisomerase-targeted drugs.
Baguley BC; Ferguson LR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):213-22. PubMed ID: 9748584
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II enzymes and mutagenicity.
Ferguson LR; Baguley BC
Environ Mol Mutagen; 1994; 24(4):245-61. PubMed ID: 7851337
[TBL] [Abstract][Full Text] [Related]
3. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
4. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
5. Assembly of nuclear matrix-bound protein complexes involved in non-homologous end joining is induced by inhibition of DNA topoisomerase II.
Kantidze OL; Iarovaia OV; Razin SV
J Cell Physiol; 2006 Jun; 207(3):660-7. PubMed ID: 16447266
[TBL] [Abstract][Full Text] [Related]
6. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerases, new targets in cancer chemotherapy.
Zijlstra JG; de Jong S; de Vries EG; Mulder NH
Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
[TBL] [Abstract][Full Text] [Related]
8. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
9. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes.
Ferguson LR; Baguley BC
Mutat Res; 1996 Aug; 355(1-2):91-101. PubMed ID: 8781579
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
[TBL] [Abstract][Full Text] [Related]
11. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
13. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
Boege F
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
[TBL] [Abstract][Full Text] [Related]
14. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Jones NJ; Ellard S; Waters R; Parry EM
Carcinogenesis; 1993 Dec; 14(12):2487-94. PubMed ID: 8269616
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity.
Agostinho M; Santos V; Ferreira F; Costa R; Cardoso J; Pinheiro I; Rino J; Jaffray E; Hay RT; Ferreira J
Cancer Res; 2008 Apr; 68(7):2409-18. PubMed ID: 18381449
[TBL] [Abstract][Full Text] [Related]
16. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
17. Analysis of expression and function of topoisomerase I and II during meiosis in male mice.
Cobb J; Reddy RK; Park C; Handel MA
Mol Reprod Dev; 1997 Apr; 46(4):489-98. PubMed ID: 9094096
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.
Meyer KN; Kjeldsen E; Straub T; Knudsen BR; Hickson ID; Kikuchi A; Kreipe H; Boege F
J Cell Biol; 1997 Feb; 136(4):775-88. PubMed ID: 9049244
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
Burden DA; Osheroff N
Biochim Biophys Acta; 1998 Oct; 1400(1-3):139-54. PubMed ID: 9748545
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase enzymes as drug targets.
Guichard SM; Danks MK
Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
